Sunday, October 1, 2023
Clinical Advances in
Despite various treatment alternatives and enhanced insulin formulations, type 2 diabetes often remains uncontrolled in many patients for far too long, thus increasing the risk for serious long-term complications. The causes of clinical inertia with respect to insulin initiation and intensification are varied and include concerns such as weight gain, risk of hypoglycemia, and cumbersome or inflexible dosing regimens. Next-generation basal insulin analogues and novel combination regimens with GLP-1 agonists may help physicians to overcome this inertia.
Supported by an independent educational grant from
See All
A slide kit on the role of insulin in T2D management, insulin intensification options and novel insulin combinations
Download
Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;12:1-10.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140-9.
Khunti K, Davies MJ, Kalra S. Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab. 2013 Aug;15(8):690-700.
Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93.
Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes. The SWITCH 1 Randomized Clinical Trial. JAMA. 2017;318:33-44.
Wysham C, Bhargava A, Chaykin L, et al. Effect Of Insulin Degludecvs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. The SWITCH 2 Randomized Clinical Trial. JAMA. 2017;318:45-56.
Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of Insulin Glargine Up-Titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. The DUAL V Randomized Clinical Trial. JAMA. 2016;315:898-907.
Buse JB, Vilsbøll T, Thurman J, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014 Nov;37(11):2926-33.
Drab SR, Philis-Tsimikas A. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action. Pharmacotherapy. 2014 Mar;34(3):291-302.
Mathieu C, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62.
Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
Philis-Tsimikas A, Brod M, Niemeyer M, et al. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013 Jun;30(6):607-22.
See All
Steering Committee Chair
Professor of Medicine; Head of Endocrinology, Laboratory of Experimental Medicine Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Leuven, Belgium
Professor of Medicine (Diabetes), Institute of Life Science, Swansea University College of Medicine, Swansea, United Kingdom
Professor of Metabolic Health, Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, Australia
Medical Director, Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
Former Associate Professor of Family Medicine, University Pierre et Marie Curie; Vice President, French Society of General Medicine, Paris, France
Corporate Vice President, SCRIPPS HEALTH (Scripps Whittier Diabetes Institute), San Diego, California
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Hanmi Pharmaceuticals; Janssen Pharmaceutical; MannKind Corporation; Medtronic, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceutical Corporation; Novo Nordisk; Pfizer Inc.; Roche Diagnostics; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceutical Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk; Sanofi; Merck Sharp & Dohme Corp.; Eli Lilly and Company; Roche Diagnostics; Abbott Laboratories; Novartis Pharmaceuticals Corporation
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cellnovo; Eli Lilly and Company; Janssen Global Services LLC; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk
has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; SERVIER
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; SERVIER
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Medtronic, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Roche; Dexcom, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Medtronic, Inc.; Merck Sharp and Dohme Corp.; Novo Nordisk; Roche; Dexcom, Inc.; Sanofi Received grants for clinical research from: Dexcom, Inc.; Novo Nordisk; Roche
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; Ipsen; Mayoly Spindler; Menarini; Merck Sharp & Dohme Corp.; Novo Nordisk; Pfizer Inc; Sanofi; Sanofi Pasteur MSD; SERVIER
Has disclosed the following relevant financial relationships:
Served as a speaker or member of a speakers bureau for: Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk; Sanofi